Highest-materiality recent filing
Calidi Biotherapeutics Q2 2026 net loss narrows to $4.2M; FDA agrees on CLD-401 path
Net loss attributable to common stockholders: $4.2M ($2.94/share) vs $5.7M ($31.75/share) in Q2 2025, adjusted for 1-for-16 reverse split.
Calidi Biotherapeutics effects 1-for-16 reverse stock split to maintain NYSE American listing
Reverse stock split at 1-for-16 ratio effective July 30, 2026; trading begins July 31 under symbol CLDI.
Stockholders approve reverse stock split (1:2 to 1:16) and equity plan increase to 1.95M shares
Elected Scott Leftwich as Class III director with 3.27M votes for, 1.38M withheld.
Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track
Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
Calidi closes $6M public offering; existing warrants amended to $0.50 exercise price
Gross proceeds of $6.03M from 12,094,631 units sold (including full over-allotment exercise).
Calidi Biotherapeutics provides corporate update; debt reduced by $3.1M, IND planned for Q4 2026
Term debt and notes payable reduced to $0.7M at Dec 31, 2025, from $3.8M at Dec 31, 2024 (unaudited).
Calidi presents positive preclinical data on CLD-401 at SITC; IND filing expected by end 2026
CLD-401 protected from immune clearance and replicates specifically in tumor cells after systemic administration.
Sold 22.5M shares (100% of its Nova Cell ownership) for $6M; consideration includes debt cancellation of ~$1.2M and deferred payments.
Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M
Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.
Calidi Biotherapeutics effects 1-for-12 reverse stock split effective August 4, 2025
Reverse stock split at ratio 1-for-12 became effective on August 4, 2025.
Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025
Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.
Calidi shareholders approve reverse stock split and 3M-share equity plan increase
Elected James Schoeneck (6.5M for) and George Peoples (6.6M for) as Class II directors.
Calidi Biotherapeutics raises $4.6M via warrant exercise at $0.70/share
Gross proceeds ~$4.6M from immediate exercise of 6,595,000 warrants at $0.70/share.
Calidi reports Q1 net loss $5.0M; CEO transition to Eric Poma; FDA clears CLD-201 IND
CEO transition: Eric Poma appointed CEO; 30+ yrs biopharma; raised >$250M at Molecular Templates.
Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director
Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.
Appointment effective April 8, 2025; one-year term with monthly consulting fee of $20,833.33.
Calidi Biotherapeutics closes $3.9M registered direct offering and private placement
Gross proceeds ~$3.9M from sale of 3.325M shares at $0.65 and pre-funded warrants for 2.728M shares.
Calidi Biotherapeutics reports Q4 net loss of $4.1M; files IND for CLD-201 solid tumor trial
Q4 2024 net loss $4.1M ($0.27/share) vs $8.2M loss ($0.23/share) in Q4 2023.
RTNova platform demonstrated killing of over 60 different tumor cell lines in preclinical models.
Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M
Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.
Calidi Biotherapeutics prices $4.25M public offering of 5M shares at $0.85/share
Priced public offering of 5,000,000 shares at $0.85 per share for gross proceeds of $4.25 million.
Calidi Biotherapeutics closes $7.5M public offering of 4.44M shares at $1.69/share
Gross proceeds ~$7.5M from 4,437,869 shares at $1.69; closed Nov 15, 2024.
Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND
Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.
NYSE American to delist Calidi Biotherapeutics warrants due to low trading price
NYSE Regulation commences delisting of Calidi warrants (CLDI WS) under Section 1001 of NYSE American Company Guide.
FDA clears IND for Calidi's CLD-101 Phase 1b/2 trial in high-grade glioma
FDA cleared Northwestern University's IND for CLD-101, a stem cell-based oncolytic virus therapy for high-grade glioma.
the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.
Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board
On August 16, 2024, Mr. George Ng, a member of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”), informed the Board that, in order to focus on increasing professional commitments outside of the Company, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of the Company’s 2024 annual shareholder meeting.
On June 20, 2024, the Board of Directors (the “Board) of Calidi Biotherapeutics, Inc. (the “Company”) appointed Dr. George Peoples as a director, effective July 1, 2024.
On May 10, 2024, Mr. David LaPre notified the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as a director of the Company, including his position on each Board committee on which he served, effective immediately.
the Board appointed Mr. David LaPre as a director to fill the vacancy in connection with Mr. Vecchiolla’s departure, effective January 1, 2024.
Mr. Thomas Vecchiolla announced that he will be resigning as a director of the Board of Directors (the “Board”) of Calidi Biotherapeutics, Inc. (the “Company”) effective January 1, 2024.
the resignation of Mr. Alfonso Zulueta as a director of the Company, including his position on audit committee of the Board, effective immediately
On October 27, 2023, the Board of Directors approved and ratified the appointment of Mr. Andrew Jackson as the Chief Financial Officer of the Company and the Compensation Committee approved and ratified the Employment Agreement with Mr. Andrew Jackson effective October 30, 2023 .
On October 23, 2023, Mr. Tony Kalajian resigned from all positions in Calidi Biotherapeutics, Inc., including his roles as Chief Accounting Officer and as interim Chief Financial Officer.
Max materiality 0.80 · Median 0.57 · Most common event other_material